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Glucocorticoid-induced polycystic kidney disease—A threshold trait.
Administration of hydrocortisone acetate (250 mg/kg) to newborn mice
caused polycystic kidney disease (PKD) of varying proportions in each
of 18 different inbred strains; none of the injected controls were
affected. All kidneys were histologically examined and scored for
degree of cyst formation using a semi-continuous (0 to 4+) grading
scheme. Results suggested that this condition is a multifactorial thresh-
old trait. For each strain, estimates of the mean and standard deviation
of normally distributed liability were determined by maximum likeli-
hood methods. Concomitant analyses showed: 1) a significant environ-
mental effect related to drug source; 2) a variation in thresholds ranging
from 0.94 (N = 46) for the Bl0.M strain to —0.71 (N = 297) for the
C57B1/6J strain; and 3) three groups of strains with different suscepti-
bility to PKD. These results are consistent with a multifactorial basis
for susceptibility to PKD. Quantitative analysis of thresholds and
liability distributions reveals that genetic, environmental and random
elements all contribute to the expression and extent of the cystic trait.
Renal morphogenesis in rodents persists into the early post-
natal period (1 to 3 weeks) so that teratogenic induction of
tubular malformations is possible before and after birth [1]. A
proportion of mice, rats, hamsters and rabbits, will develop
polycystic kidney disease (PKD) in response to postnatal ad-
ministration of exogenous glucocorticoid hormone [2—51.
In both humans and other mammals with naturally occurring
renal cysts, the various forms of PKD have been considered as
single gene disorders with mendelian modes of inheritance [61.
Our preliminary studies of glucocorticoid-induced PKD in
inbred mice showed that the proportions of affected animals
varied from strain to strain [2] and were inconsistent with
simple Mendelian ratios. This paper describes our hypothesis of
the genetic basis of PKD and the formal analysis in 18 inbred
strains of mice. The results indicate that susceptibility to
induction of PKD by hydrocortisone acetate (HCA) is multifac-
tonal and that cystic change is a threshold trait.
Methods
Experimental protocol
Breeding pairs from inbred, congenic and mutant strains of
mice (Table 1) were obtained from either Jackson Laboratories,
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(Bar Harbour, Maine, USA) or private breeding stocks. They
were maintained under the guidelines outlined by the Canadian
Council of Animal Care [71, as inbred isolates in our animal
quarters. The room was kept at 20°C with alternating 12 hours
of light and dark. For each strain, sufficient pups to maintain a
breeding stock were excluded from the study. The remaining
one day old newborns (2069 mice) were weighed and injected
intramuscularly with HCA (250 mg/kg body weight) in the
hindquarter using a 27 gauge needle. Mice injected with a
similar volume of normal saline and uninjected animals served
as controls (N> 500).
Animals from the initial survey of 18 strains were studied at
various ages between 4 and 14 days. Thereafter, all animals
were studied on day 5, as this was found to be the optimal
interval for induction of cystic changes. After sacrifice, the
kidneys were removed and placed in Trump's fixative [8]. The
tissue was processed, embedded in paraffin, sectioned and
stained with hematoxylin and eosin. The microscopic slides of
the kidney were independently read by two observers. Sections
without any demonstrable change were scored as 0 and cystic
changes were scored on an ascending scale of 1 + to 4+, as
shown in Figure 1.
Initially, all nine strains received Cortet'R Acetate, a prepa-
ration of hydrocortisone acetate (HCA) manufactured by the
Upjohn Co. of Canada (Montreal, Quebec). Because the Up-
john Company discontinued the drug, a change was made to
Hydrocortone' acetate, a preparation from Merck Sharp &
Dohme (Canada). Preliminary analysis revealed different re-
sponses to the two drug preparations, so that subsequent results
with the Merck Sharp & Dohme product (MSD study group)
and the Upjohn product (UPC study group) were analyzed
separately. Information provided by the manufacturers sug-
gested that the components of both preparations were identical,
but concentrations of non-active ingredients in one of them
were not available to us.
Analysis of proportions
Proportions of affected mice in the UPC group were com-
pared using a likelihood ratio test [9], and strains were further
classified using a technique for detecting a change in a sequence
of proportions (101. Using the method of Elston [111, intraclass
correlations (r1) were calculated for each study group as esti-
mates of heritability. These estimates, based on the ratio of the
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Table 1. PKD in 18 strains of mbred micea
Strain
Proportion
UPC MSD
B10.Gc 2/29
B10.WBC 8/46
B10.MC
YBR/WiCv.Eg0'"1
4/28
13/63
BALB/c 18/76
BALB/B 2/25
WB/ReP 2/7
DCH-TfmBlo' 21/63
3/9
DBA/2J 21/58 6/41C
C57BL/6J-bgt"
C57BL/6J-W""
6/17
31/80
CBAICaJ 64/132 13/59e
DD 85/153 51/189°
SB/Le 16/23
C3H/HeJ 226/3 16 90/238
C57BL/6Jb 226/297 37/89°
A/J 25/3
a MSD and UPC refer to the different manufacturers (Merck Sharp
Dohme and Upjohn, respectively) of hydrocortisone acetate.
b Single gene mutation on the C57BL/6J strain
Strains congenic with C57BL background
d Defined single gene phenotypes (see text)
Significantly different proportions (MSD vs. UPC)
Eg° mutation was kindly supplied by V. Chapman (Roswell
Park Memorial Institute, Buffalo, NY). The DD strain was from J.
Schiom (NIH, Bethesda, MD). The DCH-TfmBlo is from the private
stocks of one of us [39].
Estimates of proportions may not be robust because they are based
on only I litter.
additive component of the among-strain to total variance,
would tend to be inflated if used to estimate the heritability of
the trait in a random mating population instead of among inbred
strains.
Time-series analyses [12] were used to study variation of the
trait over time in strains with sufficient sample size (CBAICaJ,
DD, C3HJHeJ and C57BL/6J). These were subgrouped by
month of birth, season, generation, number of pregnancies, and
litter size.
Threshold analysis
A threshold trait can be defined as one which is only
manifested when the total contribution of the genetic and
environmental factors reaches a critical amount called the
threshold. The combination of these factors is considered to be
a variable, termed liability, and for the purpose of analysis, is
assumed to have a normal distribution (normal probability
density function) [131. This concept has been extended to
include multiple thresholds when increasing expression of a
trait is manifested as discrete changes in the phenotype [14, 15].
Conceptually, the underlying, normally distributed liability
maps into the discrete phenotypic distribution [161.
In our experiments, increasing expression of PKD was con-
tinuous, but had been grouped into quantified categories. It was
postulated by one of us that such categorization of a trait could
be treated as an empirical multinomial sampling of a truncated
continuous distribution, the truncation point being the thresh-
old. Using the graded scores of cystic change as multinomial
categories, the hypothesis that their distribution was consistent
with an underlying normal distribution was tested. There were
sufficient numbers of mice for detailed analysis in 9 out of 18
strains sacrificed on day 5.
To fit the empirical distribution to a normal probability
density function, the following log likelihood function, (with
mean, m, and variance, s2)1 up to an additive constant, was
formulated and optimized to obtain maximum likelihood esti-
mates of the mean and variance for each strain receiving either
the UPC or MSD preparation:2
2 2
l(m,s2) =
nolojs./_ e2dx + flilo8f STr== e2dx
+
n4loj e2dx
where log = loge and n1 is the number of mice in the score
category i+ (i = 0, 1, . . . , 4). From these results, estimates of
the expected values for each score were calculated. In both
study groups the goodness-of-fit with a normal distribution was
determined for each strain, for pooled subgroups of strains, and
for the pool of all strains, using likelihood ratio tests comparing
the observed and expected scores [18]. Homogeneity of distri-
butions within the defined subgroups was tested using likeli-
hood ratio tests [9]. Estimates of the thresholds (with approxi-
mate 95% confidence intervals) in units of standard deviation
from the means are given by the relation: t = —mis.
Results
None of the 500+ controls demonstrated any evidence of
cystic change. On the other hand, HCA administration induced
PKD in a varying proportion of all 18 strains (Table 1). Of the
four strains on the C57B l/6J background, the three single gene
mutations [beige (—bg), spotting (W"); and glucuronidase
negative (—Eg°) were less affected than the parent strain.
Mutant homozygotes, heterozygotes and wild-type animals
were not distinguished in the analysis of these mutations. In a
related manner, the B 10 congenic strains were minimally af-
fected as compared to the CS7BL/6J animals, although they also
derive from the same C57BL background.
There were statistically significant differences among the
proportions of affected animals in the UPC study group (D =
132.74: P = 0.0, 9d.f.). The nine strains could be classified into
three distinct subgroups (Fig. 2). The BlO.M strain, the only
member of Subgroup I, was more resistant than any of the other
strains, with less than 7% of the animals affected. Four strains
(comprising Subgroup II) with moderate resistance (<50%
'Given by
1 —(C—rn)2
f(m s2) = ___________ 0
where x is any value in the domain of the distribution [9].
2 Computerized optimization of this function was achieved using a
conjugate gradient method [171. A Fortran program was written for this
purpose and supplemented with NAG library subroutines (VAX 8800
computer Digital Equipment Corporation).
-
-
,
 
,
 
4r
 
•
—
 -
 
-
.
 
•
 
•
 
2 
l:.
t&
i. 
4 
a
 
-
t 
flit
. 
•
I 
-
.
 
t 
-
 
•
, 
—
 
.
%
,.•
*P
 
,
—
 
a
 
S 
S 
I; 
—
 
I..
 
—
 
-
 
-
-
a
 
-
-
I.-
 
-
 
-
-
.
.
 
S'
-- 
:-
 
-
 
1 
'-
-
 
•
-
 :•
%
; -•.
 
A 
I 
a
, 
—
 
•
 
.
-
 
McDonald et a!: PKD—A threshold trait 903
Fig. 1. A composite photomicrograph of kidneys demonstrating a measurement scale of severity of 0 to 4+. The left frame shows a normal (0)
kidney while each successive frame represents 1+, 2+, 3+, 4+ cyst development. Cystic changes are present in proximal, distal and collecting
tubules, the distal changes being relatively more prominent as severity increases. Glomerular tufts appear normal, but there is occasional dilatation
of Bowman's space. Various immature nephron forms can be seen in the outer cortex as these are differentiating organs (H & E: each X 90).
B10.M —
DCH-Tfm B/a
DBA/2J
C57BL/6JWv
CBAICaJ
DD
SB/Le
II
C3H/HeJ
C57BL/6J
Strain
0.0 0.2 0.4 0.6 0.8 1.0
Proportion affected
affected) were homogeneous with respect to proportion. In the
three most sensitive strains comprising Subgroup III, 70 to 76%
of animals were affected. Inclusion of the DD strain (56%
affected) in either subgroup II or III resulted in significant
non-homogenitity (D = 13.164, P = 0.001 4df. and D = 3.515,
P = 0.172) 2df, respectively).
For the five strains given both drug preparations, the propor-
III Fig. 2. Proportions of mice, from the UPC
study group, affected with polycystic kidney
disease. Data from 9 different strains were
classified and then tested for within subgroup
homogeneity [91 into Subgroups I, II, III [10].
The DD strain was not classifiable but was
homogeneous with Subgroup II in the MSD
Sub-group study group.
tions of affected animals were also homogeneous within both
Subgroups II and III but were significantly less than the
corresponding proportions in the animals receiving the UPC
preparation (P < l0 for both subgroups). In the MSD group,
homogeneity of subgroups II is preserved with inclusion of the
DD strain (D = 20.001, P = 0.0, 3 d.f.). After separation
according to drug source, examination for possible influence of
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Table 2. Threshold analysis of the UPC study group
BIOM DBA/2J DCH-TfmBlo C57BL/6J-W"
OB EXOB EX OB EXOB EX
N 46 58 63 34
no 38 38.021 38 38.329 42 42.368 18 18.589
n1 7 6.989 13 11,165 16 15.646 10 8.712
n2 1 0.946 4 5.850 5 4.433 4 4.787
n3 0 0.043 2 2.071 0 0.527 2 1.568
n4 0 0.001 1 0.585 0 0.026 0 0.344
m --0.8688 —0.6520 —0.4635
—0.1598
s 0.9237 1.5720 1.0373 1.3607
D 0.0001 0.9902 0.01 12 0.3415p * 0.3197 * 0.5590
t 0.9388 0.9406 0.3993 0.4148 0.4307 0.4468 0.0738 0.1174
CI
Statistics and results from 9 strains of mice injected with hydrocortisone acetate (Upjohn). There are observed (OB) and expected (EX) columns
for each strain. Numbers under OB except for the value of t (see below), are raw data. Numbers under EX are derived from the hypothesized
normal distributions characterized by maximum likelihood estimates of the mean and variance.
For each strain:
N, total number of mice injected.
n0, number with no evidence of PKD.
n1. . . n4, numbers with PKD in score categories I + to 4+.
m, maximum likelihood estimate of the mean.
s, maximum likelihood estimate of the standard diviation.
D, deviance. The likelihood ratio statistic for goodness-of-fit. D = 2 nI(OB} ln(nO/nI{EX}). Adjacent categories were combined when flj{Ex}<I
D is approximately distributed as chi square when the null hypothesis is true.
P, P-value associated with D. The values are not corrected for simultaneous inference, *' indicates insufficient degrees of freedom for
estimation.
t, threshold. Under OB, it is the value of z (the standard normal variate) such that the area to the left of z equals n0/N. Under EX, t = —rn/s.
CI, the number added to and subtracted from t to obtain approximate 95% confidence limits. It is based on a transformation of the diagonal
elements of the Fisher information matrix of the likelihood function.
time, season, number of pregnancies, and generation revealed
relatively wide fluctuations without regular pattern or signifi-
cantly periodicity.
The intraclass correlation estimate (r,) was 0.140, suggesting
that the cystic trait has a low heritability. The interclass
correlations within Subgroups II (r1 = 0.027) and III (r = 0.0)
suggest no intra-subgroup genetic variation with respect to the
quantal trait.
Threshold and liability distribution analysis
Summary data for the UPC group (Table 2) shows good
agreement between observed and expected values in each score
category, Likelihood ratio statistics (D) for the goodness-of-fit
showed no significant deviation from normality (P > 0.05) for
six of the seven strains in the UPC group that could be analyzed
when considered as independent tests. However, when a Bon-
ferroni correction for simultaneous inference [19] is applied, the
DD strain distribution (uncorrected P =0.0364) is also shown to
be consistent with normality. This goodness-of-fit with the
expected probability density function curves can be readily
appreciated from visual inspection of Figure 3.
Although testing of the pooled data (generating a single
probability density function for the entire UPC group) was
consistent with normality (D 1.3266; P = 0.52, 2 d.f.), the
nine strains of the UPC group were not statistically homoge-
neous (D = 177.85, P <0.001, 16 d.f.).
The distributions of Subgroups II and III, defined by differ-
ences of proportion, were different (D = 103.84, P < 0.001, 12
d.f.), but both Subgroup II (moderate resistance) (D = 8.8169,
P = 0.1841, 6 d.f.) and Subgroup III (sensitive) (D = 7.7469, P
= 0.1013, 4 d.f.) were internally homogeneous. The DD and the
Bl0.M strains could not be fitted to either subgroup.
Summary data for the five strains receiving the MSD prepa-
ration are shown in Table 3. Goodness-of-fit testing for normal-
ity was the same as for the UPC group except that the DD strain
was normally distributed and fitted quite well with Subgroup II.
The agreement between observed and expected values remains
close, but the distribution mean and calculated threshold for
any given strain are different from those for the UPC prepara-
tions. Examples of these differences are shown in Figure 4. The
variances within subgroups were homogeneous, even across
study groups, when tested using likelihood ratios or the Bartlett
statistic (P > 0.5 for both tests).
Discussion
In 1950, Baxter and Fraser first described the teratogenic
induction of cleft palate by cortisone injections into pregnant
mice [20]. Subsequent studies have amply confirmed that this
steroid-induced malformation has a genetic basis and conforms
closely to the model for multifactorial inheritance [21—251.
Our findings indicate that glucocorticoid-induced PKD also
fits the multilactorial threshold model. First, different propor-
tions develop PKD after injection with HCA in each of 18
strains of mice examined. Second, there are differences in
liability related to the presence of single gene mutations on a
constant background (C57B l/6J). Third, the severity of the
disease, among the nine strains studied in detail, has a fre-
quency distribution with significant goodness-of-fit to a normal
McDonald et al: PKD—A threshold trait 905
Table 2. Continued
CBA/CaJ DD C3H/HeJ
EX OB EX OB
SB/Le C57BL/6J
OB EX OB EX OB EX
132 153 316 23 297
68 68.930 68 70.112 90 91.347 7 6.598 71 71.898
46 42.290 58 50.391 122 121.400 8 8.287 115 111.765
14 17.438 18 25.694 81 80.189 6 5.959 82 84.697
3 3.099 8 6.098 23 20.862 1 1.881 25 25.481
1 0.243 1 0.705 0 2.202 1 0.275 4 3.159
——0.0586 0.1161 0.5533 0.5983 0.6990
1.0532 1.1074 0.9950 1.0635 0.9991
1.1779 4.3794 4.6470 0.0460 0.4060
0.2778 0.0364 0.0979 0.8302 0.8163
0.0380 0.0557 —0.1397 -—0.1048 -—0.5686 -—0.5561 -—0.5119 —0.5625 —-0.7093 —0.6996
Table 3. Threshold analysis: MSD study group
DBA/2J
OB EX
DD CBA/CaJ
EX OB EX OB
C3H/HeJ C57BL/6J
OB EXEXOB
N 41 189 59 238 89
no 35 35.141 137 137.561 46 46.090 148 147.679 52 51.956
n, 4 3.989 34 33.851 12 11.808 55 55.092 28 28.006
n2 2 1.442 15 13.662 1 1.081 26 26.356 8 8.166
0 0.358 3 3.369 0 0.021 7 7.482 1 0.841
n4 0 0.069 0 0.556 0 0.000 2 1.391 0 0.030
m —1.7168 —0.8469 —0.5945 —0.4156 —0.1994
s 1.6084 1.3969 0.7660 1.3547 0.9423
D 0.0095 0.3679 0.0131 0.2716 0.0002
p * 0.5442 * 0.8730 *
1.0522 1.0674 0.5974 0.6063 0.7710 0.7762 0.3103 0.3068 0,2128 0.2116
CI
Statistics and results from 5 strains of mice injected with hydrocortisone acetate (Merck Sharp & Dohme). The index of symbols is the same as
that of Table 2.
probability density function. And fourth, a change in the HCA
preparation consistently produced a change in the proportion of
mice affected, and a shift in the mean of the underlying liability
distribution.
Classically, in an at-risk population for a single threshold
trait, the multifactorial model assumes a set of genes affecting
expression of the trait that interact with a set of environmental
circumstances. The pool of genetic and environmental factors is
collectively called liability [13]. It is considered that in any
affected individual, a critical degree of liability—a threshold—
has been exceeded, resulting in full expression of the trait. In
this case, the underlying frequency distribution of the combi-
nations of genes and environment is assumed to be normal or
transformable to normal by appropriate scaling of measurement
[13]. It is not possible to test the assumption of normality for
any single liability distribution for a discrete phenotype.
This analysis assumes that the phenotype expression is
continuous. We consider that each strain receiving the UPC or
MSD product (Tables 2 and 3) constitutes a separate experi-
ment. Each experiment represents a separate sampling of an
underlying "pooled" liability distribution applicable to the
subgroup of which the strain is a member. Furthermore, the
strains of each subgroup can be considered samples of a
theoretically larger number of strains to which the pooled
subgroup liability applies. Goodness-of-fit tests indicate that the
underlying distributions are not significantly different from
normal. Tests for homogeneity indicate that the strains within
subgroups do not differ from one another with respect to
distribution and threshold. The apparent non-classifiability of
the DD strain in the UPC study group is most likely an accident
of sample since the MSD study group clearly places DD in
Subgroup II.
Our analysis also allows some considerations of the relative
contributions of the three basic elements contributing to a
multifactorial threshold trait: genes, environment, and chance
[26]. A normally distributed liability may follow from a simple
"polygenic" model, if alleles of many genes in the pool have
small, additive effects. By the second generation of random
mating within an at-risk population, the Hardy-Weinberg equi-
librium obtains and polygenic effects are binomially distributed.
Thus, a critical number of genes might alone be sufficient to
produce a threshold phenomenon [13]. At the other extreme is
a model in which many small environmental perturbations
predominate, also generating a normal distribution of liability
but with a threshold. In this case, gene effects are minimal.
Finally, computer modelling of random or "chaotic" effects
suggest that threshold traits with continuous liability distribu-
tions of severity can arise out of stochastic events during
organogenesis, even with single-gene traits [26].
In our model, insertion or deletion of a single genetic factor
Severity
Fig. 3. Comparison of liability distributions and observed proportions
of affected mice on the UPC study group, showing a good fit to normal.
The scale points (Ito 4) on the abcissae were determined from the mean
and variance of each normal distribution, taking the threshold (t) as 0.
For each strain, the areas to the right of the threshold (shaded) and
between successive scale points equal the expected proportions of
affected mice in the respective score categories. The areas of the
rectangles above each pair of successive points equal the observed
proportions in the score categories. Because the base of each rectangle
is I, these proportions can be read from the ordinate heights. The
curves and scale points were generated with an HP7475A plotter,
Hewlett-Packard Company, interfaced with a Vax 8800 computer,
Digital Corporation.
had the potential of changing the mean or variance of liability
and threshold. Indeed, our results demonstrate a change in both
mean and variance with the W" mutation on the C57B1/6J
strain. Further genetic analysis, is now in progress to identify
possible loci modulating liability, such as the histocompatability
loci as suggested by the change in liability of the BIO.M strain.
Distribution parameters of liability were helpful in identifying
an environmental effect. The relatively sudden decrease in
proportions of affected animals at half-way through the exper-
Severity
Fig. 4. Effect of drug preparation on liability. Symbols are: (_)
Upjohn; (. . . .) Merck Sharp & Dohme. Two representative strains are
shown. Note that both strains show a shift in the mean and therefore the
liability when administered with the MSD preparation.
iments was initially postulated to be the result of some biologic
element, such as generation, litter number or number of preg-
nancies. Effect of season was also considered, since Kalter [27]
had observed such an influence on steroid-induced cleft lip and
palate. However, time series analyses of thresholds (based on
maximum likelihood estimates of the liability parameters) elim-
inated these variables, and showed that the decrease was
directly related to a change in drug preparation. A major
confounding environmental effect was thus eliminated and a
more specific dissection of the remaining genetic and random
elements in the expression of PKD was possible. Such consid-
erations of changing liability and threshold may also apply to
studies by Gardner, Evan and Reed [28] and Werder et al [29],
who found similar changes in penetrance of PKD with shifts to
and from a germ-free environment. Furthermore, our experi-
ments demonstrate that in the presence of a well-controlled
ambient environment and in the absence of any possible genetic
variation, there is substantial variation in expressivity of PKD
within strains.
A plausible explanation may be derived from the molecular
biology of steroid action. With a uniform exposure of steroid
receptors to circulating steroid molecules, the formation of
activated steroid-receptor complexes will follow a Poisson
distribution which, in the limiting case for large numbers of
molecules, is indistinguishable from the normal distribution
[30]. It follows that there may be a critical number of receptors
that must be activated, likely at an inappropriate time in
organogenesis in order to produce a change in cell phenotype.
Assuming that kidneys will not show microscopic changes if
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insufficient numbers of cells express the steroid-activated phe-
notype, it further follows that an increasing number of altered
cells will generate increasing cystic changes that conform to a
normal distribution of severity. It is in this sense that chance
plays a role in morphogenesis, both in the development of and
extent of the trait.
This analysis of steroid-induced PKD in mice has important
implications for our understanding of PKD in man. Infantile and
adult forms of the disease are considered to be Mendelian
disorders arising from single gene defects. This interpretation
has recently received substantial support from studies showing
linkage of adult PKD to the alpha globin locus on chromosome
16 [31—32]. However, incomplete penetrance, extremely vari-
able expressivity and discordance in twins [33—35] are clinical
observations that defy simple genetic interpretation. Moreover,
reports from several different centers of linkage heterogeneity
for several kindreds suggest that more than one locus must be
involved [36—39].
Some of these discrepancies can be resolved if PKD is
considered a threshold trait in which chance is a major compo-
nent of liability. In threshold traits, even a subtle change in the
environment has the potential of changing the incidence of a
trait and, under our hypothesis, its severity. For example,
steroid exposure in utero [39] could also influence the expres-
sion of cystic change in the developing kidney. Moreover, other
loci may also play a major role in modulating liability to PKD.
Further study of the genetic basis underlying steroid induction
of PKD in mice may eventually offer a more comprehensive
explanation for the complex expression of this disease in
humans.
Acknowledgments
The work was supported by a grant from the Medical Research
Council of Canada. We thank Karen Morash, Maureen McGuire-
Grandy, and Heather Gillis for assistance in the preparation of the
manuscript.
Reprint requests to Dr. J.F.S. Crocker, Dept. of Pediatrics, I. W.K.
Children's Hospital, 5850 University Ave., Halifax, Nova Scotia, B3J
3G9 Canada.
References
1. CROCKER JFS, BROWN D, VERNIER RL: Development defects of
the kidney. Ped Clin NA 18:355—376, 1971
2. CR0CKER JFS, BLECHER SR. SAFE SH: Polycystic renal disease, in
Abnormal functional development of the heart, lungs and kidneys,
edited by KAVLOCK Ri, GRABOWSKI CT, New York, Alan R. Liss,
Inc., 1985, p. 281
3. PEREY DYE, HERDMAN RC, GOOD RA: Polycystic renal disease: A
new experimental model. Science 158:494—296, 1967
4. FILMER RB, CARONE FA, ROWLAND RG, BABCOCK JR: Adrenal
corticosteroid-induced renal cystic disease in the newborn hamster.
Am J Pathol 72:461—472, 1973
5. BAXTER TJ: Cortisone-induced renal changes in the rabbit: A
microdissection study. Brit J Exp Pathol 41:140—149, 1960
6. OGBORN MR. CROCKER iFS, BLECHER SR: Polycystic kidney
disease trends in research and diagnosis. Pediat Rev Commun
2:123—146, 1988
7. Guide to the Care and Use of Experimental Animals, vol 1.
Canadian Council on Animal Care. Ottawa, 1980
8. MCDOWELL EM: Fixation and processing, in Diagnostic electron
microscopy, vol 1, edited by TRUMP BF, JoNEs RT, New York,
John Wiley and Sons, 1978, p. 113
9. KALBFLEISCH JG: Probability and statistical inference, vol 2. New
York, Springer-Verlag New York Inc., 1985, pp. 152—159
10. WORSLEY KJ: The power of likelihood ratio and cummulative sum
tests for a change in a binomial probability. Biometrika 70:455—464,
1983
11. ELSTON RC: Estimating "heritability" of a dichotomous trait.
Biometrics 33:231—233, 1977
12. WILKINsoN L: Systat Software computer package: Time series
analysis module. Evanston, Illinois 1987
13. FALCONER DS: The inheritance of liability to certain diseases,
estimated from the incidence among relatives. Ann Hum Genet
29:51—75, 1965
14. REICH Ti, JAMES JW, MORRIS CA: The use of multiple thresholds
in determining the mode of transmission of semi-continuous traits.
Ann Hum Genet 36:163—184, 1972
15. CRow JF, KIMURA M: An introduction to population genetics
theo,y, New York, Harper and Row, 1970, pp. 225—230
16. RUTLEDGE JJ: Repeatability of Threshold Traits. Biometrics June:
395—399, 1977
17. PRESS WH, FLANNERY BP, TEUKOLSKY SA, VETTERLING WT:
Numerical Recipes: The Art of Scientific Computing, 1986, New
York, Cambridge University Press, pp. 301—307
18. MOORE DS: Tests of the chi-squared type, in Goodness of Fit
Techniques, edited by RB D'AGOSTINO, MA STEPHENS, New
York, Marcel Dekker, Inc., 1986, pp. 63—77
19. SOKAL RR, ROHLF FJ: Introduction to Biostatistics (2nd ed), New
York, WH Freeman and Company, 1987, pp. 178—179
20. BAXTER H, FRASER FC: The production of congenital defects in the
offspring of female mice treated with cortisone: A preliminary
report. McGill Med J 19:245—249, 1950
21. FRASER FC, FAINSTAT TD: The production of congenital defects in
the offspring of pregnant mice treated with cortisone. Pediatrics
8:527—533, 1951
22. FRASER FC: Relation of animal studies to the problem in man, in
Handbook of Teratology, edited by JO WILSON, FC FRASER, New
York, Plenum Press, 1977, pp. 75—96
23. BIDDLE FG, FRASER FC: Cortisone-induced cleft palate in the
mouse: A search for the genetic control of the embryonic response
trait. Genetics 85:289—302, 1977
24. FRASER FC: The genetics of cleft lip and palate: Yet another look,
in Current Research Trends in Prenatal Craniofacial Development,
edited by PRATT, CHRISTENSEN, North Holland Inc, Elsevier, 1980,
pp. 357—366
25. VEKEMANS M: The genetical difference between the DBA/2J and
C57BL/6J strains in cortisone-induced cleft palate. Can J Genet
Cytol 24:797—805, 1982
26. KURNIT DM, LAYTON WM, MATTHYSSE S: Genetics, chance and
morphogenesis. AM J Genet 41:979-995, 1987
27. KALTER H: Some sources of non-genetic variability in steroid-
induced cleft palate in mice. Teratology 13:1—10, 1976
28. GARDNER KD, EVAN AP, REED WP: Accelerated renal cyst
development in deconditioned germ-free rats. Kidney mt 29:1116—
1123, 1986
29. WERDER AA, AMOS MA, NIELSON AH, WOLFE OH: Comparative
effects of germfree and ambient environments on the development
of cystic kidney disease in the CFWWd mice. J Lab Cliii Med
103:399—407, 1984
30. KALBFLEISCH JO: Probability and statistical inference, New York,
Springer-Verlag New York Inc., 1985, pp. 128—144
31. REEDERS ST. BRUENING MH, DAVIES KE, NICHOLLS RD, JARMAN
AP, HIGGS DR. PEARSON PL, WHETHERALL DJ: A highly polymor-
phic DNA marker linked to adult polycystic kidney disease on
chromosome 16. Nature 317:542—544, 1985
32. BRUENING MH, VERWEST A, IJL0 J, SARIS JJ, KEITH T, REEDERS
ST, VAN OMMENG JB, PEARSON PL: Characterization of new
probes for diagnosis of polycystic kidney disease. Progr Clin Biol
Res 305:69—75, 1989
33. GANG DL, HERRIN JT: Infantile polycystic disease of the liver and
kidneys. Clin Nephrol 25:28—36, 1986
34. BLYTH H, OCKENDEN BG: Polycystic disease of kidneys and liver
presenting in childhood. J Med Gen 2:257—284, 1971
35. KAPLAN BS, KAPLAN P. DECHADAREVIAN JP, JEQUIER S,
O'REGAN 5, Russo P: Variable expression of autosomal recessive
polycystic kidney disease and congenital hepatic fibrosis within a
family. Am J Med Gen 29:639—647, 1988
36. KIMBERLING WJ, FAIN PR, KENYON JB, GOLDGARD, SUJANSKY
908 McDonald et a!: PKD—A threshold trait
E, GABOW PA: Linkage heterogeneity of autosomal dominant
polycystic kidney disease. N Eng! J Med 319:913—918, 1988
37. ROMEO G, DEVOTO M, COSTA 0, ET AL: A second genetic locus for
autosomal dominant polycystic kidney disease. Lancet 2:8—Il, 1988
38. NoithY S. SORENSEN AWS, BOESEN P: Non-allelic genetic hetero-
genity of autosomal dominant polycystic kidney disease. Progr Gun
BiolRes 305:83—88, 1989
39. BRISSENDEN JE, ROSCOE JM, SILVERMAN M: Assessment of a
linked DNA marker for presymptomatic diagnosis of adult polycys-
tic kidney disease in North America. (abstract) Gun Invest Med
1l:C499, 1988
40. CROCKER JFS, OGBORN MR, OZERE CD, CHALMERS KE: Critical
periods for glucocorticoid teratogenesis in the developing nephron.
(abstract) Clin Invest Med 10:C381, 1987
41. BLECHER SR: Microscopical epididymides in testicular feminiza-
tion. Nature 275:748—749, 1978
